Nayar J K, Knight J W, Ali A, Carlson D B, O'Bryan P D
University of Florida, Florida Medical Entomology Laboratory, Vero Beach 32960, USA.
J Am Mosq Control Assoc. 1999 Mar;15(1):32-42.
A technical powder of Bacillus thuringiensis serovar. israelensis (B.t.i.) (VectoBac TP, 5,000 international toxic units [ITU]/mg), an aqueous suspension (VectoBac 12AS, 1,200 ITU/mg), and a granular formulation (VectoBac CG, 200 ITU/mg) were tested in the laboratory under different biotic and abiotic, conditions for efficacy against larvae of saltwater (Aedes taeniorhynchus) and freshwater (Culex nigripalpus) mosquitoes. Second-, 3rd-, and 4th-instar larvae of Cx. nigripalpus were 1.3-3-fold more susceptible to both VectoBac TP and VectoBac 12AS than were the respective larval instars of Ae. taeniorhynchus. For each species, 2nd-instar larvae were several-fold more susceptible to these B.t.i. preparations than were the 4th instars. In test cups, larvae under lower densities exposed to B.t.i. concentrations sustained 5-9-fold higher mortalities than larvae under high-density conditions. VectoBac TP and VectoBac 12AS stayed in suspension for up to 24 h with similar larvicidal efficacy, which was greater at 32-35 degrees C than at 15-20 degrees C. At 60 degrees C maintained for 24 h, VectoBac 12AS was adversely affected 2-3-fold in terms of potency, but VectoBac TP was not affected. Significant loss of potency of both VectoBac 12AS and VectoBac TP occurred when exposed to 35-37 degrees C under high light intensity (140,000-170,000 lux) for 6 h. Increasing salinity levels from 0 (fresh water) to 50% sea water caused gradual efficacy declines of VectoBac 12AS and VectoBac TP against Ae. taeniorhynchus larvae. VectoBac CG caused insignificant initial and residual (up to 8 days) larval mortalities of both mosquito species. This formulation did not release the active ingredient of B.t.i. in any significant mosquito larvicidal concentration in surface layers of water, and the formulation was more effective in shallower water. Storage of all 3 formulations under constant laboratory and variable field conditions for up to 8 months did not produce detectable potency loss of these products.
苏云金芽孢杆菌以色列亚种(B.t.i.)的一种技术粉末(VectoBac TP,5000国际毒力单位[ITU]/毫克)、一种水悬浮液(VectoBac 12AS,1200 ITU/毫克)和一种颗粒制剂(VectoBac CG,200 ITU/毫克)在实验室中于不同生物和非生物条件下进行了测试,以评估其对咸水(致倦库蚊)和淡水(黑须库蚊)蚊子幼虫的杀灭效果。黑须库蚊的二龄、三龄和四龄幼虫对VectoBac TP和VectoBac 12AS的敏感性比致倦库蚊相应龄期的幼虫高1.3至3倍。对于每个物种,二龄幼虫对这些B.t.i.制剂的敏感性比四龄幼虫高几倍。在测试杯中,低密度条件下接触B.t.i.浓度的幼虫死亡率比高密度条件下的幼虫高5至9倍。VectoBac TP和VectoBac 12AS在悬浮液中可保持长达24小时,且杀幼虫效果相似,在32至35摄氏度时的效果比在15至20摄氏度时更好。在60摄氏度下保持24小时,VectoBac 12AS的效力受到2至3倍的不利影响,但VectoBac TP不受影响。当在高光强度(140,~170,000勒克斯)下于35至37摄氏度暴露6小时时,VectoBac 12AS和VectoBac TP的效力均出现显著损失。盐度水平从0(淡水)增加到50%海水会导致VectoBac 12AS和VectoBac TP对致倦库蚊幼虫的效力逐渐下降。VectoBac CG对两种蚊子幼虫的初始和残留(长达8天)死亡率影响不显著。该制剂在水表层中不会以任何显著的杀蚊幼虫浓度释放B.t.i.的活性成分,且该制剂在较浅水中更有效。在实验室恒定条件和野外可变条件下将所有三种制剂储存长达8个月,未导致这些产品的效力出现可检测到的损失。